Share
133 Posts.
lightbulb Created with Sketch. 50
clock Created with Sketch. 26/05/20
11:12
Share
The stock is very fresh, only listed a year ago.... hence not much awareness about it. My guess is that the people that were in the stock before placement and also got 1.30 placement were skimming a margin on that, and of course some profit takers. Once it finds a floor, it will start building and obviously there will be some catalysts to do with pre-P3 clinical development (formulation work, updates on manufacturing, human PK studies, appointments of advisers, etc). Picking something close to 1.30 on market will be a good value.
Originally posted by curis:
↑
This company would not see 2023. It is developing a drug that was previously sold by Astra Zeneca with peak sales of $1B for treatment of patients with type 2 diabetes (drug known as Byetta). That product is now of patent and sales are declining, so its a no brainer that Astra Zeneca will seriously consider to acquire an asset that their sales reps already selling, with 7 years exclusivity and potential peak sales of 500M.
Expand
Last edited by
curis :
26/05/20
